Journal
MOLECULAR GENETICS AND METABOLISM
Volume 119, Issue 3, Pages 187-206Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2016.09.002
Keywords
Primary mitochondrial disorders; Mitochondrial disease; Nutritional interventions; Dietary supplements; Medical foods; OXPHOS
Funding
- Edison
- Raptor
- Reata Pharmaceutical companies
- Stealth Peptides
- Raptor Pharmaceuticals
- Vitaflo
- NIH
- Neurovive
- Stealth Biopeptides
- Muscular Dystrophy Association
- Santhera Pharmaceuticals
- Edison Pharmaceuticals
- BioMarin
- Medical Research Council
- Wellcome Trust
- Ryan Stanford Appeal
- Lily Foundation
- International Foundation for CDKL5 Research (IFCR)
- Edison Pharmaceutical company
- Reata Pharmaceutical company
Ask authors/readers for more resources
In December 2014, a workshop entitled Nutritional Interventions in Primary Mitochondrial Disorders: Developing an Evidence Base was convened at the NIH with the goals of exploring the use of nutritional interventions in primary mitochondrial disorders (PMD) and identifying knowledge gaps regarding their safety and efficacy; identifying research opportunities; and forging collaborations among researchers, clinicians, patient advocacy groups, and federal partners. Sponsors included the NIH, the Wellcome Trust, and the United Mitochondrial Diseases Foundation. Dietary supplements have historically been used in the management of PMD due to their potential benefits and perceived low risk, even though little evidence exists regarding their effectiveness. PMD are rare and clinically, phenotypically, and genetically heterogeneous. Thus patient recruitment for randomized controlled trials (RCTs) has proven to be challenging. Only a few RCTs examining dietary supplements, singly or in combination with other vitamins and cofactors, are reported in the literature. Regulatory issues pertaining to the use of dietary supplements as treatment modalities further complicate the research and patient access landscape. As a preface to exploring a research agenda, the workshop included presentations and discussions on what PMD are; how nutritional interventions are used in PMD; challenges and barriers to their use; new technologies and approaches to diagnosis and treatment; research opportunities and resources; and perspectives from patient advocacy, industry, and professional organizations. Seven key areas were identified during the workshop. These areas were: 1) defining the disease, 2) clinical trial design, 3) biomarker selection, 4) mechanistic approaches, 5) challenges in using dietary supplements, 6) standards of clinical care, and 7) collaboration issues. Short- and long-term goals within each of these areas were identified. An example of an overarching goal is the enrollment of all individuals with PMD in a natural history study and a patient registry to enhance research capability. The workshop demonstrates an effective model for fostering and enhancing collaborations among NIH and basic research, clinical, patient, pharmaceutical industry, and regulatory stakeholders in the mitochondrial disease community to address research challenges on the use of dietary supplements in PMD. (C) 2016 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available